<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287467</url>
  </required_header>
  <id_info>
    <org_study_id>INSIGHT 006: FLU-IVIG</org_study_id>
    <nct_id>NCT02287467</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza</brief_title>
  <official_title>Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is
      usually mild, but can cause serious illness or death. The purpose of this study is to test
      the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune
      immunoglobulin or IVIG) in people who are hospitalized for severe flu.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza is responsible for thousands of hospitalizations and deaths each year in the United
      States and worldwide. One possible new treatment for the flu involves the use of IVIG, a
      blood product containing antibodies from people who have recovered from the flu or who have
      had a flu shot. The purpose of this study is to evaluate whether IVIG can reduce the severity
      and duration of flu in people who are hospitalized with the flu.

      The study will enroll participants 18 years and older who are hospitalized with the flu. The
      study will enroll participants over one or more flu seasons. Regardless of the date of
      enrollment, each participant will be in the study for about 28 days.

      At study entry (Day 0), participants will be randomly assigned to one of two groups (Arms A
      and B). Participants in both groups will receive standard of care (SOC) treatment for the
      flu, but those in Arm A will also receive one dose of IVIG and those in Arm B will receive a
      placebo for IVIG. Both IVIG and placebo will be given intravenously over at least 2 hours.

      On Day 0, before receiving IVIG or placebo, participants will undergo a symptoms assessment,
      blood collection, and a nasopharyngeal (NP) swab to collect a sample of secretions from the
      nose and throat.

      Additional study visits will occur on Days 1, 2, 3, 7, 14, and 28. Depending on the visit,
      participants may take part in the same study procedures that took place on Day 0. On Days 2,
      14, and 28, visits for participants who are no longer hospitalized may be conducted over the
      phone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 7, 2018</completion_date>
  <primary_completion_date type="Actual">June 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients in Each of 6 Clinical Status Categories on Day 7</measure>
    <time_frame>Assessed on Day 7</time_frame>
    <description>This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each of 5 Clinical Status Categories on Day 3</measure>
    <time_frame>Assessed on Day 3</time_frame>
    <description>5-category ordinal outcome assessed on day 3; clinical status ranges from death (worst) to discharged from the hospital (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each of 6 Clinical Status Categories on Day 3</measure>
    <time_frame>Measured on Day 3</time_frame>
    <description>6-category ordinal outcome evaluated on Day 3; clinical status ranges from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Favorable Outcome on Day 7</measure>
    <time_frame>Assessed on Day 7</time_frame>
    <description>Sliding dichotomy defined as non-ICU hospitalization or discharge if enrolled from ICU, and discharge if enrolled from the general ward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Discharge</measure>
    <time_frame>Measured through Day 7</time_frame>
    <description>Number of participants alive and discharged from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Measured through day 28</time_frame>
    <description>Number of participants dying through day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive and Out of Hospital</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Number and percent alive and out of hospital on day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Viral Load</measure>
    <time_frame>Day 3</time_frame>
    <description>Change in nasopharyngeal viral load from baseline to day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Re-hospitalization</measure>
    <time_frame>Day 28</time_frame>
    <description>Number and percent of participants who died or were re-hospitalized after initial discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Developing Complications</measure>
    <time_frame>Measured through Day 28</time_frame>
    <description>Number and percent of participants developing respiratory distress syndrome, acute renal failure, sepsis, pneumonia, enteritis, or bronchitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each of 6 Clinical Status Categories on Day 14</measure>
    <time_frame>Measured on day 14</time_frame>
    <description>6-category ordinal outcome measured on day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive and Out of Hospital on Day 14</measure>
    <time_frame>day 14</time_frame>
    <description>Number and percentage of participants alive and out of the hospital on Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resumption of Normal Activities by Day 14</measure>
    <time_frame>day 14</time_frame>
    <description>Participants reporting resumption of normal daily activities by Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Each of 6 Clinical Status Categories on Day 28</measure>
    <time_frame>day 28</time_frame>
    <description>6-category ordinal outcome corresponding to clinical status on day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza A-Infected Patients in Each of 6 Clinical Status Categories on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Primary 6-category ordinal outcome for participants infected with Influenza A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza B-Infected Patients in Each of 6 Clinical Status Categories on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Primary 6-category ordinal outcome for subgroup of participants infected with influenza B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH1N1 Titers at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>pH1N1 hemagglutination inhibition assay (HAI) titers among participants infected with pH1N1 using A/Cal/2009 as reference virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H3N2 Titers at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>H3N2 HAI titers among participants infected with H3N2 using A/HongKong/2014 as reference virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza B Titers at Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Flu B HAI titers among participants infected with influenza B using B/Phuket/2013 as reference virus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Influenza A</condition>
  <condition>Influenza B</condition>
  <arm_group>
    <arm_group_label>Arm A: hIVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous hyperimmune immunoglobulin (IVIG)</intervention_name>
    <description>Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
    <arm_group_label>Arm A: hIVIG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for IVIG</intervention_name>
    <description>Administered IV as 500 mL of normal saline</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Locally determined positive influenza test (by polymerase chain reaction [PCR] or
             other nucleic acid test, or by rapid antigen [Ag]) from a specimen obtained within 2
             days prior to randomization

          -  Onset of illness no more than 7 days before randomization, defined as when the
             participant first experienced at least one respiratory symptom or fever

          -  Hospitalized (or in observation unit) for influenza, with anticipated hospitalization
             for more than 24 hours. Criteria for hospitalization will be up to the individual
             treating clinician.

          -  For women of child-bearing potential: willingness to abstain from sexual intercourse
             or use at least one form of hormonal or barrier contraception through Day 28 of the
             study

          -  Willingness to have blood and respiratory samples obtained and stored

          -  NEW score greater than or equal to 2 at screening (see the protocol for more
             information on this criterion)

        Exclusion Criteria:

          -  Women who are pregnant or breast-feeding

          -  Strong clinical evidence (in the judgment of the site investigator) that the etiology
             of illness is primarily bacterial in origin

          -  Prior treatment with any investigational drug therapy within 30 days prior to
             screening

          -  History of allergic reaction to blood or plasma products (as judged by the site
             investigator)

          -  Known immunoglobulin A (IgA) deficiency

          -  A pre-existing condition or use of a medication that, in the opinion of the site
             investigator, may place the participant at a substantially increased risk of
             thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or
             clinically significant monoclonal gammopathy)

          -  Presence of any pre-existing illness that, in the opinion of the site investigator,
             would place the participant at an unreasonably increased risk through participation in
             this study

          -  Participants who, in the judgment of the site investigator, will be unlikely to comply
             with the requirements of this protocol

          -  Medical conditions for which receipt of a 500 mL volume of intravenous fluid may be
             dangerous to the participant (e.g., decompensated congestive heart failure)

          -  Receiving extracorporeal membrane oxygenation (ECMO)

          -  Suspicion that infection is due to an influenza strain or subtype other than
             A(H1N1)pdm09, H3N2, or influenza B (e.g., H5N1, H7N9)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard T. Davey, Jr., MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Fernández-Cruz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman P. Markowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah L. Pett, MD, MBBS, DTM, MRCP (UK)</last_name>
    <role>Study Chair</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center (A VRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHIO State University (OSU) Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>September 20, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiviral</keyword>
  <keyword>IVIG</keyword>
  <keyword>Hemagglutination inhibition (HAI)</keyword>
  <keyword>Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02287467/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02287467/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: hIVIG</title>
          <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive standard of care (SOC )treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Placebo</title>
          <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants in the analysis data set.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: hIVIG</title>
          <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Placebo</title>
          <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="41" upper_limit="68"/>
                    <measurement group_id="B2" value="57" lower_limit="48" upper_limit="68"/>
                    <measurement group_id="B3" value="57" lower_limit="45" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/ethnicity</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Early Warning (NEW) score</title>
          <description>National Early Warning score measured on day of randomization. The NEW score is a morbidity index based on 6 vital signs (respiratory rate, oxygen saturation, temperature, blood pressure, pulse/heart rate, level of consciousness). Each component is scored from 0 to 3 (best to worst) and the components are summed. Thus the composite score can range from 0 to 18.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B2" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B3" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients in Each of 6 Clinical Status Categories on Day 7</title>
        <description>This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
        <time_frame>Assessed on Day 7</time_frame>
        <population>All infused participants, using multiple imputation to impute outcome for 4 participants with missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each of 6 Clinical Status Categories on Day 7</title>
          <description>This is the primary outcome, a 6-category ordinal outcome ranging from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
          <population>All infused participants, using multiple imputation to impute outcome for 4 participants with missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized, in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization, using supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization, no supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, not back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio of being in a better category, as assessed using a proportional odds model. Multiple imputation techniques were used to impute an outcome for 4 patients for whom the outcome was unknown.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.33</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>Odds ratio is hIVIG vs. placebo. A value greater than 1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each of 5 Clinical Status Categories on Day 3</title>
        <description>5-category ordinal outcome assessed on day 3; clinical status ranges from death (worst) to discharged from the hospital (best).</description>
        <time_frame>Assessed on Day 3</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each of 5 Clinical Status Categories on Day 3</title>
          <description>5-category ordinal outcome assessed on day 3; clinical status ranges from death (worst) to discharged from the hospital (best).</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized, in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization, NEW score 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization, NEW score &lt; 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio for being in a better category, from a proportional odds model</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.84</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Odds ratio is for hIVIG vs placebo. An odds ratio greater than 1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each of 6 Clinical Status Categories on Day 3</title>
        <description>6-category ordinal outcome evaluated on Day 3; clinical status ranges from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
        <time_frame>Measured on Day 3</time_frame>
        <population>All participants with clinical data available on Day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each of 6 Clinical Status Categories on Day 3</title>
          <description>6-category ordinal outcome evaluated on Day 3; clinical status ranges from death (worst) to discharged from hospital with resumption of normal activities (best).</description>
          <population>All participants with clinical data available on Day 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized, in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalization, on supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ICU hospitalizaiton, no supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, not back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio for being in a better group, from a proportional odds model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.52</p_value>
            <method>Regression, Cox</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>Odds ratio is for hIVIG vs. placebo. An odds ratio &gt; 1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Favorable Outcome on Day 7</title>
        <description>Sliding dichotomy defined as non-ICU hospitalization or discharge if enrolled from ICU, and discharge if enrolled from the general ward.</description>
        <time_frame>Assessed on Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Favorable Outcome on Day 7</title>
          <description>Sliding dichotomy defined as non-ICU hospitalization or discharge if enrolled from ICU, and discharge if enrolled from the general ward.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>favorable outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unfavorable outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.20</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
            <estimate_desc>Odds ratio for hIVIG vs placebo. An odds ratio &gt; 1.0 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Discharge</title>
        <description>Number of participants alive and discharged from the hospital</description>
        <time_frame>Measured through Day 7</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Discharge</title>
          <description>Number of participants alive and discharged from the hospital</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharged alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discharged alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Deaths during hospitalization are censored after day 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.44</p_value>
            <method>Regression, Cox</method>
            <method_desc>Stratified by baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.85</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>hazard ratio is hIVIG vs placebo; a hazard ratio &gt;1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Number of participants dying through day 28.</description>
        <time_frame>Measured through day 28</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Number of participants dying through day 28.</description>
          <population>all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not die</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.40</p_value>
            <method>Regression, Cox</method>
            <method_desc>stratified by baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.48</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
            <estimate_desc>hazard ratio is for hIVIG vs placebo; a hazard ratio &lt; 1.0 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive and Out of Hospital</title>
        <description>Number and percent alive and out of hospital on day 28</description>
        <time_frame>Measured through Day 28</time_frame>
        <population>All participants with vital status known on Day 28</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive and Out of Hospital</title>
          <description>Number and percent alive and out of hospital on day 28</description>
          <population>All participants with vital status known on Day 28</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Alive and out of hospital</title>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Died or hospitalized</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.74</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.38</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
            <estimate_desc>odds ratio is for hIVIG vs placebo; an odds ratio &gt; 1.0 favors hIVIG</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Viral Load</title>
        <description>Change in nasopharyngeal viral load from baseline to day 3</description>
        <time_frame>Day 3</time_frame>
        <population>Participants with viral load results at both baseline and day 3. Participants with undetectable viral load results at baseline are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Viral Load</title>
          <description>Change in nasopharyngeal viral load from baseline to day 3</description>
          <population>Participants with viral load results at both baseline and day 3. Participants with undetectable viral load results at baseline are excluded.</population>
          <units>log10 RNA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread=".16"/>
                    <measurement group_id="O2" value="-2.32" spread=".17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.49</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted for baseline RNA, geographic region, and influenza subtype</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.26</ci_lower_limit>
            <ci_upper_limit>.54</ci_upper_limit>
            <estimate_desc>Change is calculated as day 3 - baseline. Difference in changes is hIVIG - placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Re-hospitalization</title>
        <description>Number and percent of participants who died or were re-hospitalized after initial discharge</description>
        <time_frame>Day 28</time_frame>
        <population>all participants with data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Re-hospitalization</title>
          <description>Number and percent of participants who died or were re-hospitalized after initial discharge</description>
          <population>all participants with data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.93</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>Odds ratio is for hIVIG vs placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Developing Complications</title>
        <description>Number and percent of participants developing respiratory distress syndrome, acute renal failure, sepsis, pneumonia, enteritis, or bronchitis</description>
        <time_frame>Measured through Day 28</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Developing Complications</title>
          <description>Number and percent of participants developing respiratory distress syndrome, acute renal failure, sepsis, pneumonia, enteritis, or bronchitis</description>
          <population>all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.81</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
            <estimate_desc>odds ratio is for hIVIG group vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each of 6 Clinical Status Categories on Day 14</title>
        <description>6-category ordinal outcome measured on day 14</description>
        <time_frame>Measured on day 14</time_frame>
        <population>participants with observed data on day 14</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each of 6 Clinical Status Categories on Day 14</title>
          <description>6-category ordinal outcome measured on day 14</description>
          <population>participants with observed data on day 14</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized in ICU</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized on supplement oxygen</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized not on supplemental oxygen</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged, not back to normal activities</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged, back to normal activities</title>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportional odds for being in a better category</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.55</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in the pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>Odds ratio (hIVIG vs placebo) of being in a better category. An odds ratio &gt; 1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive and Out of Hospital on Day 14</title>
        <description>Number and percentage of participants alive and out of the hospital on Day 14</description>
        <time_frame>day 14</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive and Out of Hospital on Day 14</title>
          <description>Number and percentage of participants alive and out of the hospital on Day 14</description>
          <population>all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.77</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.5</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
            <estimate_desc>odds ratio is for hIVIG vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resumption of Normal Activities by Day 14</title>
        <description>Participants reporting resumption of normal daily activities by Day 14</description>
        <time_frame>day 14</time_frame>
        <population>Participants with observed data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Resumption of Normal Activities by Day 14</title>
          <description>Participants reporting resumption of normal daily activities by Day 14</description>
          <population>Participants with observed data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.34</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
            <estimate_desc>odds ratio is expressed as hIVIG vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Each of 6 Clinical Status Categories on Day 28</title>
        <description>6-category ordinal outcome corresponding to clinical status on day 28</description>
        <time_frame>day 28</time_frame>
        <population>participants with observed data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each of 6 Clinical Status Categories on Day 28</title>
          <description>6-category ordinal outcome corresponding to clinical status on day 28</description>
          <population>participants with observed data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized, on supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized, not on supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, not back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.73</p_value>
            <p_value_desc>adjusted for baseline clinical status, region, and participation in pilot study</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.50</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>odds ratio (hIVIG vs placebo) is for being in a better category. An odds ratio &gt;1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza A-Infected Patients in Each of 6 Clinical Status Categories on Day 7</title>
        <description>Primary 6-category ordinal outcome for participants infected with Influenza A</description>
        <time_frame>Day 7</time_frame>
        <population>all participants infected with influenza A</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Influenza A-Infected Patients in Each of 6 Clinical Status Categories on Day 7</title>
          <description>Primary 6-category ordinal outcome for participants infected with Influenza A</description>
          <population>all participants infected with influenza A</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized on supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized not on supplemental oxygen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, not back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharged, back to normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Multiple imputation was used to estimate the outcome for 3 participants for whom the outcome was partially unknown.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.82</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in the pilot study.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>Odds ratio (hIVIG vs placebo) is for being in a better category.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza B-Infected Patients in Each of 6 Clinical Status Categories on Day 7</title>
        <description>Primary 6-category ordinal outcome for subgroup of participants infected with influenza B</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Influenza B-Infected Patients in Each of 6 Clinical Status Categories on Day 7</title>
          <description>Primary 6-category ordinal outcome for subgroup of participants infected with influenza B</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized in ICU</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized on supplemental oxygen</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalized not on supplemental oxygen</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged, not back to normal activities</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged, back to normal activities</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Multiple imputation was used to estimate the outcome for one participant.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.02</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for baseline clinical status, region, and participation in pilot study</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>8.42</ci_upper_limit>
            <estimate_desc>Odds ratio (hIVIG vs placebo) for a better outcome. An odds ratio &gt; 1 favors the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pH1N1 Titers at Day 7</title>
        <description>pH1N1 hemagglutination inhibition assay (HAI) titers among participants infected with pH1N1 using A/Cal/2009 as reference virus</description>
        <time_frame>Day 7</time_frame>
        <population>participants infected with pH1N1 with HAI titers measured at day 7</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>pH1N1 Titers at Day 7</title>
          <description>pH1N1 hemagglutination inhibition assay (HAI) titers among participants infected with pH1N1 using A/Cal/2009 as reference virus</description>
          <population>participants infected with pH1N1 with HAI titers measured at day 7</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="374"/>
                    <measurement group_id="O2" value="229" spread="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HAI measurements were log-transformed to compute treatment differences and the model was adjusted for baseline titer.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.18</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>longitudinal regression with adjustment for baseline titer</method_desc>
            <param_type>ratio of geometric means</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Ratio of hIVIG group to placebo group. A ratio &gt; 1.0 indicates higher titers for the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>H3N2 Titers at Day 7</title>
        <description>H3N2 HAI titers among participants infected with H3N2 using A/HongKong/2014 as reference virus</description>
        <time_frame>Day 7</time_frame>
        <population>participants infected with H3N2 with HAI titers measured at day 7</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>H3N2 Titers at Day 7</title>
          <description>H3N2 HAI titers among participants infected with H3N2 using A/HongKong/2014 as reference virus</description>
          <population>participants infected with H3N2 with HAI titers measured at day 7</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" spread="291"/>
                    <measurement group_id="O2" value="225" spread="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.13</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>longitudinal analysis of log-transformed titers adjust for baseline titer.</method_desc>
            <param_type>ratio of geometric means</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Ratio of geometric means of hIVIG vs placebo. A ratio &gt;1.0 indicates higher titers in the hIVIG group on day 7.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza B Titers at Day 7</title>
        <description>Flu B HAI titers among participants infected with influenza B using B/Phuket/2013 as reference virus</description>
        <time_frame>Day 7</time_frame>
        <population>participants infected with influenza B with HAI titers measured at day 7</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: hIVIG</title>
            <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo</title>
            <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza B Titers at Day 7</title>
          <description>Flu B HAI titers among participants infected with influenza B using B/Phuket/2013 as reference virus</description>
          <population>participants infected with influenza B with HAI titers measured at day 7</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="161"/>
                    <measurement group_id="O2" value="84" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.78</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>log-transformed titers adjusted for baseline titer</method_desc>
            <param_type>ratio of geometric means</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>ratio of geometric mean for hIVIG vs placebo. A ratio &gt; 1.0 indicates higher titers at day 7 for the hIVIG group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <desc>Serious adverse events plus all grade 3 and 4 adverse events, as graded according to the National Institute of Health Division of AIDS (DAIDS) toxicity table.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: hIVIG</title>
          <description>Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (IVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Intravenous hyperimmune immunoglobulin (IVIG): Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Placebo</title>
          <description>Participants will receive a single infusion of placebo for IVIG (saline), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
Placebo for IVIG: Administered IV as 500 mL of normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Internal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vocal cord paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dysthymic disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Davey</name_or_title>
      <organization>NIAID</organization>
      <phone>301-496-8029</phone>
      <email>rdavey@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

